Glycosylated extracellular mucin domains protect against SARS-CoV-2 infection at the respiratory surface.
Journal
PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
received:
09
02
2023
accepted:
21
07
2023
revised:
29
08
2023
medline:
31
8
2023
pubmed:
10
8
2023
entrez:
10
8
2023
Statut:
epublish
Résumé
Mucins play an essential role in protecting the respiratory tract against microbial infections while also acting as binding sites for bacterial and viral adhesins. The heavily O-glycosylated gel-forming mucins MUC5AC and MUC5B eliminate pathogens by mucociliary clearance. Transmembrane mucins MUC1, MUC4, and MUC16 can restrict microbial invasion at the apical surface of the epithelium. In this study, we determined the impact of host mucins and mucin glycans on epithelial entry of SARS-CoV-2. Human lung epithelial Calu-3 cells express the SARS-CoV-2 entry receptor ACE2 and high levels of glycosylated MUC1, but not MUC4 and MUC16, on their cell surface. The O-glycan-specific mucinase StcE specifically removed the glycosylated part of the MUC1 extracellular domain while leaving the underlying SEA domain and cytoplasmic tail intact. StcE treatment of Calu-3 cells significantly enhanced infection with SARS-CoV-2 pseudovirus and authentic virus, while removal of terminal mucin glycans sialic acid and fucose from the epithelial surface did not impact viral entry. In Calu-3 cells, the transmembrane mucin MUC1 and ACE2 are located to the apical surface in close proximity and StcE treatment results in enhanced binding of purified spike protein. Both MUC1 and MUC16 are expressed on the surface of human organoid-derived air-liquid interface (ALI) differentiated airway cultures and StcE treatment led to mucin removal and increased levels of SARS-CoV-2 replication. In these cultures, MUC1 was highly expressed in non-ciliated cells while MUC16 was enriched in goblet cells. In conclusion, the glycosylated extracellular domains of different transmembrane mucins might have similar protective functions in different respiratory cell types by restricting SARS-CoV-2 binding and entry.
Identifiants
pubmed: 37561789
doi: 10.1371/journal.ppat.1011571
pii: PPATHOGENS-D-23-00249
pmc: PMC10464970
doi:
Substances chimiques
Mucins
0
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
CA-125 Antigen
0
Polysaccharides
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1011571Informations de copyright
Copyright: © 2023 Chatterjee et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
J Virol. 2005 Dec;79(24):15511-24
pubmed: 16306622
Int Rev Cell Mol Biol. 2009;276:105-59
pubmed: 19584012
Nature. 2022 Jul;607(7917):97-103
pubmed: 35255492
Nat Biotechnol. 2018 Jun;36(5):411-420
pubmed: 29608179
J Biol Chem. 2020 Sep 11;295(37):12910-12934
pubmed: 32661197
Eur Respir J. 2020 Apr 16;55(4):
pubmed: 32217658
Front Med (Lausanne). 2021 Nov 23;8:668024
pubmed: 34888316
Cells. 2021 Sep 02;10(9):
pubmed: 34571942
mBio. 2020 Nov 12;11(6):
pubmed: 33184103
Front Med Technol. 2021 Jan 13;2:614652
pubmed: 35047894
Proc Natl Acad Sci U S A. 2020 Sep 1;117(35):21299-21307
pubmed: 32817557
Nat Commun. 2021 Jan 8;12(1):134
pubmed: 33420022
EMBO J. 2021 Mar 1;40(5):e105912
pubmed: 33283287
Am J Respir Crit Care Med. 2020 Dec 15;202(12):1636-1645
pubmed: 32726565
Nat Commun. 2021 Jul 1;12(1):4070
pubmed: 34210959
Int J Antimicrob Agents. 2020 May;55(5):105960
pubmed: 32251731
Elife. 2021 Apr 09;10:
pubmed: 33835028
Nat Commun. 2020 Oct 28;11(1):5453
pubmed: 33116139
EMBO J. 2019 Feb 15;38(4):
pubmed: 30643021
Glycobiology. 2012 Jun;22(6):736-56
pubmed: 22183981
Arch Virol. 2020 Jul;165(7):1517-1526
pubmed: 32322993
Annu Rev Physiol. 2008;70:431-57
pubmed: 17850209
Cell Rep Med. 2020 Nov 17;1(8):100145
pubmed: 33225317
J Virol. 2015 Feb;89(4):1954-64
pubmed: 25428871
J Innate Immun. 2017;9(3):281-299
pubmed: 28052300
PLoS Pathog. 2019 Feb 4;15(2):e1007566
pubmed: 30716138
Cell. 2020 Nov 12;183(4):1043-1057.e15
pubmed: 32970989
Mucosal Immunol. 2017 Nov;10(6):1581-1593
pubmed: 28327617
Novartis Found Symp. 2002;248:3-12; discussion 12-9, 277-82
pubmed: 12568485
Am J Physiol Lung Cell Mol Physiol. 2010 Apr;298(4):L558-63
pubmed: 20081068
Glycobiology. 2021 Nov 18;31(10):1245-1253
pubmed: 33909065
Physiol Rep. 2021 Jan;9(1):e14701
pubmed: 33373502
Med Hypotheses. 2021 Nov;156:110680
pubmed: 34592563
J Med Virol. 2021 Feb;93(2):582-584
pubmed: 32776556
Protein Cell. 2020 Sep;11(9):680-687
pubmed: 32671793
Am J Respir Crit Care Med. 2001 Mar;163(4):983-8
pubmed: 11282777
Int Rev Cell Mol Biol. 2013;303:139-202
pubmed: 23445810
J Mol Biol. 2021 Feb 19;433(4):166762
pubmed: 33340519
Lancet Microbe. 2020 May;1(1):e2-e3
pubmed: 32835319
mBio. 2021 Apr 6;12(2):
pubmed: 33824202
JCI Insight. 2021 Oct 8;6(19):
pubmed: 34448730
Am J Respir Cell Mol Biol. 2008 Mar;38(3):263-8
pubmed: 18079492
Nat Commun. 2020 Mar 27;11(1):1620
pubmed: 32221306
J Virol Methods. 2010 Nov;169(2):365-74
pubmed: 20709108
Biochem Soc Trans. 2018 Oct 19;46(5):1099-1106
pubmed: 30154090
J Virol. 2014 Nov;88(22):13221-30
pubmed: 25187545
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Cell. 2023 Jan 5;186(1):112-130.e20
pubmed: 36580912
Science. 2020 Jul 3;369(6499):50-54
pubmed: 32358202
Proc Natl Acad Sci U S A. 2021 Oct 5;118(40):
pubmed: 34583992
Nat Genet. 2022 Aug;54(8):1078-1089
pubmed: 35879412
Mucosal Immunol. 2013 Mar;6(2):379-92
pubmed: 22929560
Proc Natl Acad Sci U S A. 2022 Apr 19;119(16):e2119680119
pubmed: 35353667
J Intern Med. 2008 Apr;263(4):432-9
pubmed: 18298483